Biggest News Aggregation in the World
📰 Arrive Technologies News

Arrive Technologies News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Arrive Technologies. Real-time updates on events, politics, business and more.

Deucravacitinib maintains efficacy through 2 years in psoriasis

MILAN — Clinical efficacy was maintained with long-term use of deucravacitinib in plaque psoriasis, according to study results presented at the European Academy of Dermatology and Venereology Congress. “Many of the drugs we use lose efficacy over time, but we now have 2-year data of deucravacitinib, and it is a completely flat line. Patients who did well continue to do just as well 2
Evelo Biosciences Kristen Dowd Eli Lilly Incyte Byrebeccal Forand Forte Biosciences Castle Biosciences
Source: healio.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science